The pharmacological landscape for PSD is also being reshaped by insights into adiponectin's role in neuronal health, offering avenues to modulate inflammatory responses and alleviate depressive symptoms post-stroke through neuroplasticity regulation [249]. The gene discussed is ADIPOQ; the disease is Stroke.